Rituximab for myasthenia gravis

Katherine Dodd, Fiona Clay, Anne-Marie Forbes, Yann Shern Keh, James Miller, Jon Sussman, James Lilleker

Research output: Contribution to journalArticlepeer-review


This is a protocol for a Cochrane Review (intervention). The objectives are as follows:

To assess:

the safety and efficacy, as assessed by the effect on disease severity or functional ability and the burden of alternative treatment, of rituximab (including biosimilar variants) for the treatment of myasthenia gravis in adults; and

outcomes and adverse effects between different patient subgroups, and treatment strategies, in order to aid treatment choice for individuals, and to inform policymakers about those most likely to benefit.
Original languageEnglish
JournalCochrane Database of Systematic Reviews (protocol)
Publication statusPublished - 5 Apr 2023


Dive into the research topics of 'Rituximab for myasthenia gravis'. Together they form a unique fingerprint.

Cite this